Top Tweets for #TechnologyForLicensing
๐ฉป#TechnologyforLicensing: ๐ข๐๐ฌ๐ญ๐๐จ๐ฉ๐จ๐ซ๐จ๐ฌ ๐๐๐ซ๐๐๐ง, a novel, AI-enhanced chest X-ray tool
The tool forecasts #osteoporosis and its future risk for fracture at the hip and spine using a routine chest X-ray with high accuracy (93โ98%).
This innovation provides a quick (one-minute), cost-effective AI diagnostic for mass screening, even in resource-limited areas.
We're open to discussing licensing or co-development partnerships with companies and industry stakeholders looking to make a global impact.
To learn more about this #technology, please reach out to the CCAMP Office of Technology Transfer (#OTT):
๐https://t.co/3TmR0hurYo
โ๏ธ080 6718 5322
๐Office of Technology Transfer (OTT), Centre for Cellular and Molecular Platforms (C-CAMP), GKVK Post, Bellary Road, Bangalore 560065, Karnataka, India.
@Taslimarif_IND @PrinSciAdvOff @DBTIndia @BIRAC_2012 @AIMtoInnovate @NITIAayog @GoI_MeitY @meitystartuphub @startupindia @ITBTGoK @Ktech_biotech @Startup_Kar @EpsilonLtd @hindrays @INDIA_RMS @GEHealthCare @PhilipsHealth @SiemensHealth @Harrison_ai @GoogleHealth @AstraZeneca @bmsnews #DiagnoHealthcare
#TechnologyForLicensing: CCAMP and Institute of Plasma Research (IPR) have jointly filed a patent for their "Cold Atmospheric Plasma-Based (CAP) Air Disinfection Device"
The solution addresses limitations of existing technologies for air purification and is capable of:
* Neutralising pathogens
* Trapping/removing PM 2.5 and PM 10 particles rendering improved ambient air quality
* Faster disinfection and purification of air covering the entire range of pollutants, pathogens, SPM and VoCs.
Advantages of the design:
* The device has been validated on the ESKAPE range of bacterial pathogens, fungal pathogens and viral organisms by an independent NABL-accredited lab.
* The device can be customised as a stand-alone or as an attachment with existing filtration devices and AHU systems.
* It is scalable as the cartridge is modular, and the product can be scaled to suit the application area. Plasma Clean is the next-gen in air purification.
If you are interested in knowing more, please reach out to the C-CAMP Office of Technology Transfer (#OTT): ๐ง[email protected]
@Taslimarif_IND @PrinSciAdvOff @DBTIndia @BIRAC_2012 @kris_sg @honeywell @Dyson @BlueairUS @Bry_Air @IQAir @BlueStarLtd
๐ฉป#TechnologyforLicensing: iOsteoporos Screen, a novel, AI-enhanced chest X-ray tool
The tool forecasts #osteoporosis and its future risk for fracture at the hip and spine using a routine chest X-ray with high accuracy (93โ98%).
This innovation provides a quick (one-minute), cost-effective AI diagnostic for mass screening, even in resource-limited areas.
We're open to discussing licensing or co-development partnerships with companies and industry stakeholders looking to make a global impact.
To learn more about this #technology, please reach out to the CCAMP Office of Technology Transfer (#OTT):
๐https://t.co/3TmR0hurYo
โ๏ธ080 6718 5322
๐Office of Technology Transfer (OTT), Centre for Cellular and Molecular Platforms (C-CAMP), GKVK Post, Bellary Road, Bangalore 560065, Karnataka, India.
@Taslimarif_IND
@PrinSciAdvOff
@DBTIndia @BIRAC_2012
@AIMtoInnovate @NITIAayog
@GoI_MeitY @meitystartuphub @startupindia
@ITBTGoK @Startup_Kar
@EpsilonLtd @hindrays @INDIA_RMS @GEHealthCare @PhilipsHealth @SiemensHealth @Harrison_ai @GoogleHealth @AstraZeneca @bmsnews
#DiagnoHealthcare
#TechnologyForLicensing: A novel topical formulation for treating pre-cancerous lesions/early-stage skin cancer in invasive squamous cell carcinoma (SCC), the second most common type of skin #cancer.
๐๐ก๐ ๐ฉ๐ซ๐จ๐๐ฅ๐๐ฆ
SCCs start as premalignant lesions called Actinic Keratoses (AKs), and the standard treatment involves the use of 5-fluorouracil (5-FU), a topical medication. However, 5-FU can cause severe side effects, including intense redness, itching, crusting, and pain.
๐๐จ๐ฅ๐ฎ๐ญ๐ข๐จ๐ง
The novel topical formulation, developed and successfully tested by C-CAMPโs Discovery-to-Innovation Accelerator (DIA) program in collaboration with @DBT_CDFD on syngeneic mice and human xenograft models, showed significant tumour growth reduction with no toxicity in preliminary in vivo models.
๐๐๐ฒ ๐ฉ๐ซ๐จ๐ฉ๐๐ซ๐ญ๐ข๐๐ฌ
This novel formulation comprises a novel component used alone or combined with 5-FU. The topical application showed no dermal toxicity in animal models. The molecule shows potent immunomodulatory and anti-inflammatory activity and significantly improved efficacy over 5-FU alone in vivo.
If you are interested in knowing more and want to co-develop this with us, please reach out to the CCAMP Office of Technology Transfer (#OTT):
โ๏ธ[email protected], [email protected]
โ๏ธ080 6718 5322
@Taslimarif @PrinSciAdvGoI
@DBTIndia @IndiaDST @BIRAC_2012
@kris_sg
@abbvie @abcuro @cgoncology @ImmuneOnc @Roche @Novartis @NovartisCancer @AstraZeneca
@bmsnews @pfizer @Amgen @AmgenOncology @PeptidreamInc @proteinqure @ferring @halozymeinc @GileadSciences @BostonONCOLOGY
#TechnologyForLicensing
We are looking for industry partners to scale up a novel immunomodulator in the #respiratory infection space.
Developed and translated by the CCAMP translation research programme, Respi-Protect helps to prevent and treat respiratory infections such as the flu and COVID-19 through intranasal delivery.
Respi-Protect's USP: A non-invasive, easily deliverable option for the prevention and treatment of various respiratory infections.
What is the technology?
It is an immunomodulatory peptide-based immune-boosting mechanism with broad-spectrum activity against viruses like Influenza and potentially SARS-CoV-2
How does it work?
Respi-Protect works by activating the innate immune system in the nasal mucosa, which is the initial entry point for respiratory pathogens. This activation is achieved by modulating the TLR2/4 pathways.
Studies conducted on animal models of influenza and COVID-19 have shown that Respi-Protect can serve both prophylactically and therapeutically, reducing lung damage and viral titers.
We invite #industry partners and other interested stakeholders to explore partnership opportunities with us. If you are interested in knowing more about this technology, please reach out to the CCAMP Office of Technology Transfer (#OTT):
๐ง[email protected], [email protected]
๐ท080 6718 5322
@Taslimarif @PrinSciAdvOff @PrinSciAdvGoI @DBTIndia @IndiaDST @BIRAC_2012
@SiemensHealth @Boehringer @Novartis @NovartisIndia @biogen @EliLillyandCo @AurigenePharma @sanofi @IndiaSanofi @Cipla_Global @ZydusUniverse @benedicphar
#TechnologyForLicensing CCAMP and Institute of Plasma Research (IPR) have jointly filed a patent for their "Cold Atmospheric Plasma-Based (CAP) Air Disinfection Device"
The solution addresses limitations of the existing technologies for air purification and is
capable of:
* Neutralising pathogens
* Trapping/removing PM 2.5 and PM 10 particles rendering improved ambient air quality
* Faster disinfection and purification of air covering the entire range of pollutants, pathogens, SPM and VoCs.
Advantages of the design:
* The device has been validated on the ESKAPE range of bacterial pathogens, fungal pathogens and viral organisms by an independent NABL-accredited lab.
* The device can be customised as a stand-alone or as an attachment with existing filtration devices and AHU systems.
* It is scalable as the cartridge is modular, and the product can be scaled to suit the application area.
Plasma Clean is the next-gen in air purification.
If you are interested in knowing more, please reach out to the C-CAMP Office of Technology Transfer (#OTT): ๐ง[email protected] ๐080 6718 5322
@Taslimarif @PrinSciAdvOff
@DBTIndia @BIRAC_2012
@kris_sg @honeywell @Dyson @BlueairUS @Bry_Air @IQAir @BlueStarLtd
#TechnologyForLicensing
We are looking for industry partners to scale up a novel immunomodulator in the respiratory infection space.
Developed and translated by the CCAMP translation research programme, Respi-Protect helps to prevent and treat respiratory infections such as the flu and COVID-19 through intranasal delivery.
Respi-Protect's USP: A non-invasive, easily deliverable option for the prevention and treatment of various respiratory infections.
What is the technology?
It is an immunomodulatory peptide-based immune-boosting mechanism with broad-spectrum activity against viruses like Influenza and potentially SARS-CoV-2
How does it work?
Respi-Protect works by activating the innate immune system in the nasal mucosa, which is the initial entry point for respiratory pathogens. This activation is achieved by modulating the TLR2/4 pathways.
Studies conducted on animal models of influenza and COVID-19 have shown that Respi-Protect can serve both prophylactically and therapeutically, reducing lung damage and viral titers.
We invite #industry partners and other interested stakeholders to explore partnership opportunities with us. If you are interested in knowing more about this technology, please reach out to the CCAMP Office of Technology Transfer (#OTT):
๐ง[email protected], [email protected]
๐ท080 6718 5322
@Taslimarif @BIRAC_2012 @PrinSciAdvOff @PrinSciAdvGoI @DBTIndia @IndiaDST
@SiemensHealth @Boehringer @Novartis @NovartisIndia @biogen @EliLillyandCo @AurigenePharma @sanofi @IndiaSanofi @Cipla_Global @ZydusUniverse
#TechnologyForLicensing: Researchers at CCAMP, in collaboration with @BRIC_CDFD, have successfully developed & tested in mice a novel topical formulation that shows significantly accelerated complex wound healing through promoting regeneration of tissues!
The Problem: The risk factor for complex foot ulcers is as high as 15-25% in diabetic patients, as per a global study conducted in 2018.
Efficient wound healing is a major challenge in the case of diabetic wounds/ foot ulcers, pressure ulcers, and venous leg ulcers.
Impaired wound healing greatly impacts physical, psychological, social, and economic aspects for patients, affecting their quality of life and even calling for amputations in certain difficult cases.
Current Scenario: Frequent surgical debridement, antibiotic dressings, or recombinant growth factor injections are the solutions employed now.
All have limitations ranging from the requirement of skilled medical personnel, secondary antimicrobial resistance, low efficacy and high cost.
The new formulation's performance: On a head-to-head with a marketed product, in-vivo data showed that the two proprietary components of the new formulation have significantly better:
a) Wound healing
b) Collagen deposition in diabetic animals.
We believe it will also be useful in the treatment of other complex wounds like pressure ulcers and burns.
We are inviting licensing interests.
To know more, please reach out to the CCAMP Office of Technology Transfer (#OTT):
๐ง[email protected]
โ๏ธ080 6718 5322
@Taslimarif @DBTIndia @PrinSciAdvOff @kris_sg
@BIRAC_2012 @Convatec @MDT_Diabetes @cardinalhealth @SmithNephewPLC @integra_life @JNJNews @MiMedx @Coloplast_WCare @orgoholdingsinc @3M
#TechnologyForLicensing CCAMP and Institute of Plasma Research (IPR) have jointly filed a patent for their "Cold Atmospheric Plasma-Based (CAP) Air Disinfection Device"
The solution addresses limitations of the existing technologies for air purification and is
capable of:
* Neutralising pathogens
* Trapping/removing PM 2.5 and PM 10 particles rendering improved ambient air quality
* Faster disinfection and purification of air covering the entire range of pollutants, pathogens, SPM and VoCs.
Advantages of the design:
* The device has been validated on the ESKAPE range of bacterial pathogens, fungal pathogens and viral organisms by an independent NABL-accredited lab.
* The device can be customised as a stand-alone or as an attachment with existing filtration devices and AHU systems.
* Plasma-Clean is scalable as the cartridge is modular, and the product can be scaled to suit the application area.
Plasma Clean is the next-gen in air purification.
If you are interested in knowing more, please reach out to the C-CAMP Office of Technology Transfer (#OTT):
๐ง[email protected]
๐080 6718 5322
@Taslimarif @BIRAC_2012 @PrinSciAdvOff @DBTIndia @kris_sg @honeywell @Dyson @BlueairUS @Bry_Air @IQAir @BlueStarLtd
#TechnologyForLicensing
We are looking for industry partners to scale up a novel immunomodulator in the respiratory infection space.
Developed and translated by the CCAMP translation research programme, Respi-Protect helps to prevent and treat respiratory infections such as the flu and COVID-19 through intranasal delivery.
Respi-Protect's USP: A non-invasive, easily deliverable option for the prevention and treatment of various respiratory infections.
What is the technology?
It is an immunomodulatory peptide-based immune-boosting mechanism with broad-spectrum activity against viruses like Influenza and potentially SARS-CoV-2
How does it work?
Respi-Protect works by activating the innate immune system in the nasal mucosa, which is the initial entry point for respiratory pathogens. This activation is achieved by modulating the TLR2/4 pathways.
Studies conducted on animal models of influenza and COVID-19 have shown that Respi-Protect can serve both prophylactically and therapeutically, reducing lung damage and viral titers.
We invite #industry partners and other interested stakeholders to explore partnership opportunities with us. If you are interested in knowing more about this technology, please reach out to the CCAMP Office of Technology Transfer (#OTT):
๐ง[email protected], [email protected]
๐ท080 6718 5322
@Taslimarif @BIRAC_2012 @SiemensHealth @Boehringer @Novartis @NovartisIndia @biogen @EliLillyandCo @AurigenePharma @sanofi @IndiaSanofi @Cipla_Global @ZydusUniverse @PrinSciAdvOff @PrinSciAdvGoI @DBTIndia @IndiaDST
#TechnologyforLicensing: Introducing #PlasmaClean, a novel air purification plus decontamination technology.
The solution addresses the limitations of the existing technologies for air purification and is capable of:
๐ Neutralising pathogens
๐Trapping/removing PM 2.5 and PM 10 particles rendering improved ambient air quality
๐Faster disinfection and purification of air covering the entire range of pollutants, pathogens, SPM and VoCs
Advantages of design:
๐The device has been validated on the ESKAPE range of bacterial pathogens, fungal pathogens and viral organisms
๐It can be customised as a stand-alone as well as an attachment with existing filtration devices and AHU systems
๐The device is scalable as the cartridge is modular, and the product can be scaled for the application area
If you are interested to know more, please reach out to the C-CAMP Office of Technology Transfer (#OTT): ๐ง [email protected], [email protected] โ๏ธ080 6718 5322
@Taslimarif @DBTIndia @BIRAC_2012 @PrinSciAdvOff @kris_sg @honeywell @Dyson @BlueairUS @IQAir @BlueStarLtd @godrejaer
@BreatheEasyLabs
#TechnologyForLicensing
We are looking for industry partners to scale up a novel immunomodulator in the respiratory infection space.
Developed and translated by the CCAMP translation research programme, Respi-Protect helps to prevent and treat respiratory infections such as the flu and COVID-19 through intranasal delivery.
Respi-Protect's USP: A non-invasive, easily deliverable option for the prevention and treatment of various respiratory infections.
What is the technology?
It is an immunomodulatory peptide-based immune-boosting mechanism with broad-spectrum activity against viruses like Influenza and potentially SARS-CoV-2
How does it work?
Respi-Protect works by activating the innate immune system in the nasal mucosa, which is the initial entry point for respiratory pathogens. This activation is achieved by modulating the TLR2/4 pathways.
Studies conducted on animal models of influenza and COVID-19 have shown that Respi-Protect can serve both prophylactically and therapeutically, reducing lung damage and viral titers.
We invite #industry partners and other interested stakeholders to explore partnership opportunities with us. If you are interested in knowing more about this technology, please reach out to the CCAMP Office of Technology Transfer (#OTT):
๐ง[email protected], [email protected]
๐ท080 6718 5322
@Taslimarif @BIRAC_2012 @SiemensHealth @Boehringer @Novartis @NovartisIndia @biogen
@EliLillyandCo @AurigenePharma @sanofi @IndiaSanofi @Cipla_Global @ZydusUniverse @PrinSciAdvOff @PrinSciAdvGoI @DBTIndia @IndiaDST
#TechnologyforLicensing: Plasma Clean, a novel air purification plus decontamination technology.
The solution addresses the limitations of the existing technologies for air purification and is capable of:
๐Neutralising pathogens
๐Trapping/removing PM2.5 & PM10 particles
๐Faster disinfection and purification of air covering the entire range of pollutants, pathogens, SPM and VoCs
Advantages of design:
*Validated on the ESKAPE range of bacterial pathogens, fungal pathogens & viral organisms
*Can be customised as a stand-alone as well as an attachment with existing filtration devices & AHU systems
*Scalable as the cartridge is modular and the product can be scaled for the application area
Interested in knowing more?
Please get in touch with the CCAMP Office of Technology Transfer (#OTT):
๐ง[email protected], [email protected] โ๏ธ080 6718 5322
@Taslimarif @BIRAC_2012 @PrinSciAdvOff @kris_sg @honeywell @Dyson @BlueairUS @Bry_Air @IQAir @BlueStarLtd @GodrejAppliance @BreatheEasyLabs @HuaweiIndia @Philips
๐ฉป#TechnologyforLicensing: iOsteoporos Screen, a novel, AI-enhanced chest X-ray tool
The tool forecasts #osteoporosis and its future risk for fracture at the hip and spine using a routine chest X-ray with high accuracy (93โ98%).
This innovation provides a quick (one-minute), cost-effective AI diagnostic for mass screening, even in resource-limited areas.
We're open to discussing licensing or co-development partnerships with companies and industry stakeholders looking to make a global impact.
To learn more about this #technology, please reach out to the CCAMP Office of Technology Transfer (#OTT):
๐https://t.co/3TmR0hurYo
โ๏ธ080 6718 5322
๐Office of Technology Transfer (OTT), Centre for Cellular and Molecular Platforms (C-CAMP), GKVK Post, Bellary Road, Bangalore 560065, Karnataka, India.
@Taslimarif @BIRAC_2012 @DBTIndia @PrinSciAdvOff @AIMtoInnovate @NITIAayog @ITBTGoK @meitystartuphub @EpsilonLtd @hindrays @INDIA_RMS #DiagnoHealthcare
#TechnologyForLicensing: A novel topical formulation for treating pre-cancerous lesions/early-stage skin cancer in invasive squamous cell carcinoma (SCC), the second most common type of skin cancer.
๐๐ก๐ ๐ฉ๐ซ๐จ๐๐ฅ๐๐ฆ
SCCs start as premalignant lesions called Actinic Keratoses (AKs), and the standard treatment involves the use of 5-fluorouracil (5-FU), a topical medication. However, 5-FU can cause severe side effects, including intense redness, itching, crusting, and pain.
๐๐จ๐ฅ๐ฎ๐ญ๐ข๐จ๐ง
The novel topical formulation, developed and successfully tested by C-CAMPโs Discovery-to-Innovation Accelerator programme in collaboration with @DBT_CDFD on syngeneic mice and human xenograft models, showed significant tumour growth reduction with no toxicity in preliminary in vivo models.
๐๐๐ฒ ๐ฉ๐ซ๐จ๐ฉ๐๐ซ๐ญ๐ข๐๐ฌ
This novel formulation comprises a novel component used alone or combined with 5-FU. The topical application showed no dermal toxicity in animal models. The molecule shows potent immunomodulatory and anti-inflammatory activity and significantly improved efficacy over 5-FU alone in vivo.
If you are interested in knowing more and want to co-develop this with us, please reach out to the CCAMP Office of Technology Transfer (#OTT):
โ๏ธ[email protected], [email protected]
โ๏ธ080 6718 5322
@Taslimarif @BIRAC_2012 @PrinSciAdvGoI @kris_sg @abbvie @abcuro @eurofarma @cgoncology @ImmuneOnc
#TechnologyForLicensing: Respi-Protect, a novel immunomodulator for the prevention and treatment of respiratory infections such as the flu and COVID-19 through intranasal delivery.
Respi-Protect's USP: A non-invasive, easily deliverable option for the prevention and treatment of various respiratory infections.
What is the technology?
It is an immunomodulatory peptide-based immune-boosting mechanism with broad-spectrum activity against viruses like Influenza and potentially SARS-CoV-2
How does it work?
Respi-Protect works by activating the innate immune system in the nasal mucosa, which is the initial entry point for respiratory pathogens. This activation is achieved by modulating the TLR2/4 pathways.
Studies conducted on animal models of influenza and COVID-19 have shown that Respi-Protect can serve both prophylactically and therapeutically, reducing lung damage and viral titers.
We invite #industry partners and other interested stakeholders to explore partnership opportunities with us. If you are interested in knowing more about this technology, please reach out to the CCAMP Office of Technology Transfer (#OTT):
๐ง [email protected], [email protected] ๐ท080 6718 5322
@Taslimarif @BIRAC_2012 @SiemensHealth @Boehringer @Novartis @NovartisIndia @biogen @EliLillyandCo @AurigenePharma @sanofi @IndiaSanofi @Cipla_Global @ZydusUniverse @PrinSciAdvOff @DBTIndia
#TechnologyForLicensing: Introducing Respi-Protect, a novel immunomodulator for the prevention and treatment of respiratory infections such as the flu and COVID-19 through intranasal delivery.
Respi-Protect's USP: A non-invasive, easily deliverable option for the prevention and treatment of various respiratory infections.
What is the technology?
It is an immunomodulatory peptide-based immune-boosting mechanism with broad spectrum activity against viruses like Influenza and potentially SARS-CoV2
How does it work?
Respi-Protect works by activating the innate immune system in the nasal mucosa, which is the initial entry point for respiratory pathogens. This activation is achieved by modulating the TLR2/4 pathways.
Studies conducted on animal models of influenza and COVID-19 have shown that Respi-Protect can serve both prophylactically and therapeutically, reducing lung damage and viral titers.
We invite #industry partners and other interested stakeholders to explore partnership opportunities with us. If you are interested in knowing more about this technology, please reach out to the CCAMP Office of Technology Transfer (#OTT):
๐ง [email protected], [email protected] ๐ท080 6718 5322
@Taslimarif @BIRAC_2012 @SiemensHealth @Boehringer @Novartis @NovartisIndia @biogen @EliLillyandCo @AurigenePharma @sanofi @IndiaSanofi @Cipla_Global @ZydusUniverse @PrinSciAdvOff @DBTIndia
#TechnologyforLicensing: Plasma Clean, a novel air purification plus decontamination technology.
The solution addresses the limitations of the existing technologies for air purification and is capable of:
๐Neutralising pathogens
๐Trapping/removing PM2.5 & PM10 particles
๐Faster disinfection and purification of air covering the entire range of pollutants, pathogens, SPM and VoCs
Advantages of design:
*Validated on the ESKAPE range of bacterial pathogens, fungal pathogens & viral organisms
*Can be customised as a stand-alone as well as an attachment with existing filtration devices & AHU systems
*Scalable as the cartridge is modular and the product can be scaled for the application area
Interested in knowing more?
Please get in touch with the CCAMP Office of Technology Transfer (#OTT):
๐ง[email protected], [email protected] โ๏ธ080 6718 5322
@Taslimarif @BIRAC_2012 @PrinSciAdvOff @kris_sg @honeywell @Dyson @BlueairUS @Bry_Air @IQAir @BlueStarLtd @GodrejAppliance @BreatheEasyLabs @HuaweiIndia @Philips
๐ฉป#TechnologyforLicensing: iOsteoporos Screen, a novel, AI-enhanced chest X-ray tool.
The tool forecasts #osteoporosis and its future risk for fracture at the hip and spine using a routine chest X-ray with high accuracy (93โ98%).
This innovation provides a quick (one-minute), cost-effective AI diagnostic for mass screening, even in resource-limited areas.
We're open to discussing licensing or co-development partnerships with companies and industry stakeholders looking to make a global impact.
To learn more about this #technology, please reach out to the CCAMP Office of Technology Transfer (#OTT):
๐https://t.co/3TmR0hurYo
โ๏ธ080 6718 5322
๐Office of Technology Transfer (OTT), Centre for Cellular and Molecular Platforms (C-CAMP), GKVK Post, Bellary Road, Bangalore 560065, Karnataka, India.
@Taslimarif @BIRAC_2012 @DBTIndia @PrinSciAdvOff @AIMtoInnovate @NITIAayog
@ITBTGoK @meitystartuphub @EpsilonLtd @hindrays
@INDIA_RMS #DiagnoHealthcare
#TechnologyforLicensing: Plasma Clean, a novel air purification plus decontamination technology.
The solution addresses the limitations of the existing technologies for air purification and is capable of:
๐Neutralising pathogens
๐Trapping/removing PM2.5 & PM10 particles
๐Faster disinfection and purification of air covering the entire range of pollutants, pathogens, SPM and VoCs
Advantages of design:
*Validated on the ESKAPE range of bacterial pathogens, fungal pathogens & viral organisms
*Can be customised as a stand-alone as well as an attachment with existing filtration devices & AHU systems
*Scalable as the cartridge is modular and the product can be scaled for the application area
Interested in knowing more? Please get in touch with the CCAMP Office of Technology Transfer (#OTT):
๐ง [email protected], [email protected] โ๏ธ080 6718 5322
@Taslimarif @BIRAC_2012 @PrinSciAdvOff @kris_sg
@honeywell @Dyson @BlueairUS @Bry_Air @IQAir
@BlueStarLtd @GodrejAppliance @BreatheEasyLabs
Last Seen Hashtags on Sotwe
bigpussy
gรถttenลikiล
Seen from Turkey
lewatdrivethru
Seen from United Kingdom
Ukraine
Seen from United States
men sextoy
Seen from Thailand
Teenagegirls() +filter:native_video
Seen from Canada
ู
ููุง_ุญุตุฑูุงุช
Seen from Egypt
leak
Seen from Mexico
teenageโ
Seen from Malaysia
ํ๋จ์ค
Seen from Turkey
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.2M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
109.3M followers
Narendra Modi
@narendramodi
106.9M followers
Rihanna
@rihanna
97.4M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.6M followers
KATY PERRY
@katyperry
87M followers
Taylor Swift
@taylorswift13
80.8M followers
Lady Gaga
@ladygaga
72.4M followers
Kim Kardashian
@kimkardashian
69.5M followers
Virat Kohli
@imvkohli
68.9M followers
YouTube
@youtube
68.6M followers
Bill Gates
@billgates
63.5M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61.5M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
60.1M followers